Characterizing SAPHO With 68Ga-FAPI PET/CT

Summary

68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation. Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of SAPHO than 18F-FDG PET/CT.

Timeline

Start

2020-06-08

Primary completion

2021-06

Completion

2021-07

Drugs

Indications